Health ❯ Healthcare

Medications

Weight Loss Weight Loss Drugs GLP-1 Drugs Side Effects Weight Management GLP-1 Agonists Diabetes Proton Pump Inhibitors GLP-1 GLP-1 Receptor Agonists

5 ARTICLES

3d ago

Samsung and MGH Launch Trial Using Galaxy Watch to Track Muscle Loss on GLP‑1 Therapy

It tests whether watch-collected heart rate, activity, and body-composition data using Samsung Health guidance can help detect and limit muscle loss during GLP‑1 weight-loss treatment.

4 ARTICLES

4d ago

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

7 ARTICLES

last wk.

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

6 ARTICLES

2w ago

Autism Leucovorin Prescriptions Jump 2,000% After Media and White House Promotion

4 ARTICLES

2w ago

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

4 ARTICLES

2w ago

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

5 ARTICLES

2w ago

Meta-Analysis Backs Low-Dose Digitalis for Heart Failure With Fewer Worsening Events

7 ARTICLES

4w ago

Ashley Graham Calls GLP-1 Weight-Loss Craze a 'Smack in the Face' to Body Positivity

3 ARTICLES

4w ago

Study Links GLP-1 Weight-Loss Drugs to Hair Shedding With Rapid Weight Loss

15 ARTICLES

4w ago

Lancet Trial Finds Semaglutide Sharply Reduces Heavy Drinking in Patients With Obesity

8 ARTICLES

4w ago

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

6 ARTICLES

4w ago

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

4 ARTICLES

last mo.

New Data Tie GLP-1 Drugs’ Broad Benefits to Inflammation

6 ARTICLES

last mo.

Teddi Mellencamp Says Doctor Denied GLP-1 Weight-Loss Drugs During Cancer Treatment

8 ARTICLES

last mo.

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

9 ARTICLES

last mo.

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

3 ARTICLES

last mo.

Triple Low-Dose Pill Cuts Repeat Brain-Bleed Strokes by 39%, NEJM Trial Finds

Medications

Samsung and MGH Launch Trial Using Galaxy Watch to Track Muscle Loss on GLP‑1 Therapy

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

GoodRx Launches $14.99 'Companion' Membership to Cut Everyday Health Costs

Oral GLP‑1 Approval and New Trials Push Weight‑Loss Drugs Into Mass Market

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Autism Leucovorin Prescriptions Jump 2,000% After Media and White House Promotion

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

Meta-Analysis Backs Low-Dose Digitalis for Heart Failure With Fewer Worsening Events

Never miss stories about

Medications

Ashley Graham Calls GLP-1 Weight-Loss Craze a 'Smack in the Face' to Body Positivity

Study Links GLP-1 Weight-Loss Drugs to Hair Shedding With Rapid Weight Loss

Lancet Trial Finds Semaglutide Sharply Reduces Heavy Drinking in Patients With Obesity

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

New Data Tie GLP-1 Drugs’ Broad Benefits to Inflammation

Teddi Mellencamp Says Doctor Denied GLP-1 Weight-Loss Drugs During Cancer Treatment

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

Triple Low-Dose Pill Cuts Repeat Brain-Bleed Strokes by 39%, NEJM Trial Finds

Never miss stories about

Medications